Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

FDA Commissioner Marty Makary called these changes “common-sense reforms” that could expedite the development of cell and ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

Cellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after ...

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

Driven by rapid clinical translation, industrial-scale allogeneic production, and sustained public–private investment, the ...

Kincell Bio, a leading contract development and manufacturing organization (CDMO) in cell therapy, today announced the ...

The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...

Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved safety profile of Aldveron's ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Five months ago, J&J also revealed its plan to spend $2 billion over the next 10 years to operate a 160,000-square-foot ...